Market Place
Sourcing Support
Incyte wins injunction to block Sun`s Leqselvi launch
05 Nov 2024 //
FIERCE PHARMA
Lilly and EVA Pharma Collaborate to Expand Baricitinib Access in Africa
05 Sep 2024 //
PR NEWSWIRE
Aclaris Sells OLUMIANT Royalties To OMERS Life Sciences For Up To $31.5M
16 Jul 2024 //
GLOBENEWSWIRE
FDA Confirms Paragraph IV Patent Litigation for Baricitinib Tablets
20 Nov 2023 //
FDA
Eli Lilly’s alopecia drug Olumiant off to positive start with doctors
15 Mar 2023 //
ENDPTS
EMA backs restrictions on certain immune-regulating drugs
12 Nov 2022 //
BIOPHARMADIVE
JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
01 Nov 2022 //
EUROPEANPHARMACEUTICALREVIEW
EMA limits use of JAK inhibitors for at-risk groups in wake of safety concerns
29 Oct 2022 //
ENDPTS
FDA loosens marketing rules for authorized Covid drugs, but will it move needle?
28 Oct 2022 //
ENDPTS
Eli Lilly receives marketing authorisation for baricitinib
04 Oct 2022 //
PHARMATIMES
Trio of therapies reduces risk of death in patients with severe COVID-19
11 Aug 2022 //
EUROPEAN PHARMACEUTICAL REVIEW
FDA Confirms Para IV Patent Litigation for Baricitinib tablets.
26 Jul 2022 //
FDA
Eli Lilly`s Olumiant is first FDA-approved alopecia treatment
14 Jun 2022 //
FIERCEPHARMA
In flurry of activity, EMA issues nods for Sanofi, Lilly drugs
21 May 2022 //
FIERCEPHARMA
CHMP Recommends Approval of Lilly and Incyte`s OLUMIANT in Alopecia Areata
20 May 2022 //
PRNEWSWIRE
FDA approves Lilly, Incyte’s Olumiant for hospitalised patients with COVID-19
12 May 2022 //
EXPRESS PHARMA
Lilly`s Olumiant gets full FDA nod for COVID patients on oxygen
12 May 2022 //
FIERCEPHARMA
UK health service rolls out arthritis drug Baricitinib to treat COVID
06 May 2022 //
ET HEALTH
Nearly 40% of Adults with Alopecia were treated in Lilly`s Phase 3 Studies
26 Mar 2022 //
PRNEWSWIRE
Arthritis drug shown to reduce risk of COVID death in large UK trial
03 Mar 2022 //
REUTERS
EMA initiates safety review on JAK inhibitors; Galapagos woes continue
12 Feb 2022 //
ENDPTS
Computer predicted life saving benefit of Baricitinib for ventilated COVID
07 Feb 2022 //
WORLDPHARMANEWS
Lilly`s Olumiant got some bad news in lupus and eczema
29 Jan 2022 //
FIERCEPHARMA
WHO recommends GSK-Vir and Lilly’s drugs for Covid-19 treatment
17 Jan 2022 //
PHARMACEUTICAL-TECHNOLOGY
WHO recommends two new drugs, baricitinib & sotrovimab to treat Covid-19
17 Jan 2022 //
PHARMABIZ
AbbVie, Pfizer and Lilly JAK meds slapped with new warnings
07 Dec 2021 //
FIERCEPHARMA
Eli Lilly files patent litigation against 20 Indian companies on baricitinib
19 Nov 2021 //
PHARMABIZ
OLUMIANT® Long-Term Safety Profile Established Up to 9.3Y in Integrated Analysis
09 Nov 2021 //
PRNEWSWIRE
OLUMIANT Positive Data for Alopecia Areata
30 Sep 2021 //
PRNEWSWIRE
Oral JAK inhibitors unlikely to be totally shut out in eczema by box warning
29 Sep 2021 //
CLINICALTRIALSARENA
U.S. FDA allows Lilly`s COVID-19 drug to be taken without remdesivir
30 Jul 2021 //
TOI
Incyte`s Jakafi falls victim to FDA`s JAK scrutiny
09 Jun 2021 //
FIERCEPHARMA
NATCO signs Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India
17 May 2021 //
PRESS RELEASE
Lilly signs two pacts with MSN Labs and Torrent Pharma, for Covid drug
14 May 2021 //
THEHINDUBUSINESSLINE
Dr Reddy`s inks licensing pact with Eli Lilly for COVID-19 treatment drug
11 May 2021 //
INDIATIMES
Lilly accelerating baricitinib`s availability in India
04 May 2021 //
PRESS RELEASE
NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19
04 May 2021 //
PRESS RELEASE
EMA starts evaluating use of Olumiant in hospitalised COVID-19 patients
30 Apr 2021 //
EMA
Lilly to seek first FDA nod in autoimmune hair loss, Olumiant`s II trial win
24 Apr 2021 //
FIERCE PHARMA
OLUMIANT® Showed Improvements in the Severity and Extent of Atopic Dermatitis
22 Apr 2021 //
PRNEWSWIRE
Lilly to seek first approval of an autoimmune drug for hair loss
22 Apr 2021 //
BIOPHARMADIVE
Lilly and Incyte`s Baricitinib Improved Hair Regrowth for Alopecia Areata
19 Apr 2021 //
PRNEWSWIRE
Lilly and Incyte announce results from the Phase 3 COV study of baricitinib
07 Apr 2021 //
PRNEWSWIRE
Lilly and Incyte communicate review extension of snda for baricitinib
06 Apr 2021 //
PRNEWSWIRE
AI uncovers Eli Lilly`s drug Olumiant as potential Alzheimer`s treatment
10 Mar 2021 //
FIERCE BIOTECH
Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3
03 Mar 2021 //
PRNEWSWIRE
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
14 Dec 2020 //
NEJM
Baricitinib plus remdesivir shows promise for treating COVID-19
11 Dec 2020 //
NIH
Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients EUA
11 Dec 2020 //
PRNEWSWIRE
Trial to compare dexamethasone and baricitinib in hospitalised COVID-19 patients
27 Nov 2020 //
EUROPEANPHARMACEUTICALREVIEW
Lilly scores FDA EUA for Olumiant in COVID-19, its 2nd therapeutic option
21 Nov 2020 //
FIERCEPHARMA
Eli Lilly another EUA as regulators wave through its Olumiant + remdesivir combo
20 Nov 2020 //
ENDPTS
Eli Lilly arthritis drug gets FDA OK for emergency use to treat COVID-19
19 Nov 2020 //
SEEKING ALPHA
Chronic disease biotech Sigilon Therapeutics files for a $100 million IPO
13 Nov 2020 //
RENAISSANCECAPITAL
Baricitinib treatment linked to reduced mortality in COVID-19 patients
13 Nov 2020 //
MEDICALEXPRESS
Baricitinib Improves Signs, Symptoms of Severe Atopic Dermatitis Refractory
05 Nov 2020 //
FIRSTWORLDPHARMA
Lilly, Incyte tout new baricitinib data in eczema
03 Nov 2020 //
PHARMATIMES
Fall Clinical Dermatology 2020: Lilly & Incyte Showcase Positive for Baricitinib
29 Oct 2020 //
BIOSPACE
EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib
29 Oct 2020 //
PRNEWSWIRE
Coronavirus recovery drug approved for use in eczema
27 Oct 2020 //
EVENINGEXPRESS
